PHASE I CLINICAL-PHARMACODINETIC INVESTIGATION OF DEOXYCOFORMYCIN

本研究将（1）确定对低剂量 晚期恶性肿瘤患者的DCFin;（2）确定 药物的毒性，包括器官特异性，时间过程， 轻度至中度患者的可预测性和可逆性 肾功能不全vs肾功能正常患者;（3） 确定肾功能损害患者中DCF的安全剂量 功能;（4）比较患者中DCF的药代动力学 肾功能受损患者vs肾功能正常患者 功能

This study will (1) determine the therapeutic response to low-dose DCFin in patients with advanced malignancies; (2) determine the toxicity of the drug including organ specificity, time course, predictability and reversibility in patients with mild to moderate renal insufficiency vs patients with normal renal function; (3) to determine the safe dose of DCFin in patients with impaired renal function; and (4) to compare pharmacokinetics of DCFin in patients with impaired renal function vs patients with normal renal function.